

A novel seizure-induced synaptotagmin gene identified by differential display

JOSEPH M. BABITY*, JOHN N. ARMSTRONG*†‡, J.-CHRISTOPHE L. PLUMIER*‡, R. WILLIAM CURRIE*‡,
AND HAROLD A. ROBERTSON*†

*Laboratory of Molecular Neurobiology, Departments of †Pharmacology and ‡Anatomy and Neurobiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada B3H 4H7

Communicated by Ruth Sager, Dana–Farber Cancer Institute, Boston, MA, December 23, 1996 (received for review November 27, 1996)

ABSTRACT Systemic administration of kainic acid, a cyclic analogue of glutamate, produces many of the clinical features of human temporal lobe epilepsy and status epilepticus in rats, including the induction of motor convulsions and the degeneration of neurons in the hippocampus and piriform cortex. Differential display PCR was used to identify mRNAs that are differentially expressed between degenerating and nondegenerating tissues in the brain after kainic acid-induced seizure activity. A novel cDNA fragment expressed in the degenerating hippocampus and piriform cortex, but not in the nondegenerating parietal cortex, was identified, cloned, and sequenced. This novel cDNA fragment identified a new member of the synaptotagmin gene family that is rapidly and transiently induced in response to seizure activity. Differential expression of this synaptotagmin gene, *syt X*, was confirmed by Northern blot analysis and *in situ* hybridization. This novel, inducible synaptotagmin gene may provide a direct link between seizure-induced neuronal gene expression and subsequent modulation of synaptic structure and function.

Differential display PCR allows the identification of differentially expressed genes by using PAGE to display PCR-amplified cDNA fragments between two or more mRNA populations (1, 2). Differential display PCR was used to identify changes in gene expression that occur in degenerating areas of the rat brain after kainic acid-induced status epilepticus (3, 4). In this model, kainate-induced excitotoxicity leads to delayed neuronal cell death in the hippocampus and piriform cortex but not in the parietal cortex (5). Seizure activity is characterized by the rapid transcriptional activation of immediate early genes whose gene products are believed to control the expression of downstream genes associated with delayed neuronal degeneration (6). We used a differential display strategy that examined gene expression in three different brain tissues over a 12-h time period after kainic acid administration. This differential display strategy allowed us to compare gene expression in the hippocampus and piriform cortex, two brain regions that undergo excitotoxicity-induced neuronal degeneration, with gene expression in the parietal cortex, a region that does not undergo neuronal degeneration (7). Differential display patterns were examined 3, 6, and 12 h after systemic kainic acid administration. These time points were chosen to identify genes that are rapidly induced in response to kainic acid-induced seizures (8) and potential downstream target genes associated with excitotoxicity-induced neuronal degeneration.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.

Copyright © 1997 by THE NATIONAL ACADEMY OF SCIENCES OF THE USA
0027-8424/97/942638-4\$2.00/0
PNAS is available online at <http://www.pnas.org>.

MATERIALS AND METHODS

Animals. Adult male Sprague Dawley rats (250–275 g) were injected i.p. with kainic acid (12 mg/kg; Sigma) or a similar volume of vehicle (100 mM PBS). Animal behavior was then monitored for 1–2 h for characteristic signs of status epilepticus. Animals were killed 3, 6, 12, and 24 h after kainic acid administration. Animals that were injected with kainic acid but did not show signs of status epilepticus were used as controls.

RNA Isolation. Tissues used for RNA isolation were rapidly dissected, snap frozen, and stored in liquid nitrogen until used. Total cellular RNA was isolated from frozen tissue using TRIzol (GIBCO/BRL). Total RNA samples used in differential display experiments were treated with RQ1 RNase-free DNase (Promega) to remove contaminating chromosomal DNA. Poly(A)⁺ RNA was isolated using the Mini RiboSep mRNA Isolation Kit (Collaborative Research).

Differential Display Analysis. Reverse transcription of total RNA and differential display analysis were as described (2) and were analyzed on a 6% polyacrylamide DNA sequencing gel. Recovery and reamplification of the *syt X* cDNA fragment from the differential display gel was also as described (2).

Isolation of *syt X* cDNA Sequence. The *syt X* differential display cDNA fragment was subcloned into the pCR II vector (Invitrogen) and sequenced using the T7 Sequencing Kit (Pharmacia). Primer sequences derived from the differential display cDNA fragment were used to obtain additional cDNA sequence information via 5'-rapid amplification of cDNA ends using the Marathon cDNA Amplification Kit (CLONTECH).

Preparation of *syt X* Probes. The *syt X* cDNA probe used for Northern blot analysis corresponding to nucleotides 810–1553 was agarose gel purified using the Qiaex purification resin (Qiagen) and ³²P-labeled using Ready-To-Go DNA Labeling Beads (Pharmacia) (–dCTP). The oligonucleotide probe used for *in situ* hybridization, 5'-TCAGCGTCTAGTCCAGTTCGACACACACCT-3', corresponding to nucleotides 1524–1553 and was chosen based on the low degree of nucleotide similarity to other synaptotagmin genes. The oligonucleotide probe was ³²P-labeled using the 3'-End Labeling Kit (Amersham).

Northern Blot Analysis. Poly(A)⁺ RNA was isolated using the RiboSep mRNA Isolation Kit (Collaborative Research). Denatured RNA samples (2 μg) were electrophoresed in 1.0% agarose–formaldehyde gels, transferred to ZetaProbe GT membrane (Bio-Rad), fixed by UV irradiation, and hybridized with a ³²P-labeled cDNA probe prepared from a gel-purified insert. Hybridization and washing conditions were as described (9). Filters were exposed to film at –70°C with an intensifying screen. Normalization for loading was done using the Bio-Rad Model GS-690 Imaging Densitometer and MOLECULAR ANALYST software.

In Situ Hybridization. *In situ* hybridization was as described (7). The oligonucleotide probe used in this experiment, 5'-

Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. U85513).

‡To whom reprint requests should be addressed.

TCAGCGTCTAGTCCAGTTCGACACACACCT-3', was chosen based on the low degree of nucleotide similarity to other synaptotagmin genes.

Database Searches and Protein Alignment. Database searches and sequence alignment were done using the FASTA and BLAST search servers at the National Center for Biotechnology Information (10). Protein alignments were assembled using the CLUSTALW program at the Baylor College of Medicine, Houston.

RESULTS AND DISCUSSION

Identification and Cloning of Synaptotagmin X. Differential display analysis was used to identify tissue-specific changes in gene expression in response to kainic acid-induced seizure activity. We identified a 228-bp cDNA fragment that appeared to be differentially expressed in the hippocampus and piriform cortex of animals that displayed status epilepticus (Fig. 1). This cDNA fragment was not detected in the parietal cortex or in control animals that were injected with kainic acids but did not exhibit seizure activity. Sequence analysis of the cDNA fragment revealed a high degree of similarity to members of the synaptotagmin gene family (10–12). Approximately 1 × 10⁶ plaques of a poly(A)⁺-primed λZAP II rat hippocampus cDNA library (Stratagene) were screened using the differential display cDNA fragment. However, no positive clones were isolated with this method, suggesting a low level of *syt X* gene expression in the absence of seizure activity.

Additional cDNA sequences were obtained using rapid amplification of cDNA ends (Fig. 2). The predicted amino acid sequence and overall structure identify the protein as a novel member of the synaptotagmin gene family, which we designated synaptotagmin X (11, 13–18). Synaptotagmin genes are characterized by an amino acid sequence that contains five distinct regions. These consist of an N-terminal, intravesicular sequence of variable length, a transmembrane domain, a cytoplasmic region of variable length, two highly conserved C2 domains, and a short C-terminal tail. Within the cytoplasmic region located between the transmembrane domain and the conserved C2 domains, the *syt X* gene contains additional highly conserved amino acid sequences found in *syt VI* and another synaptotagmin gene, p65C, isolated from the marine ray (19) (Fig. 3). The high degree of amino acid sequence conservation observed in this region suggests that these sequences are functionally important and may define a functionally distinct class of synaptotagmin proteins.




FIG. 1. Differential display of mRNA comparing gene expression among hippocampus, piriform cortex, and parietal cortex after kainic acid administration. Only a portion of the autoradiogram is shown. C, 3, 6, and 12 denote control, 3 h, 6 h, and 12 h, respectively. Differential display reactions were performed in duplicate using 5'-TTTTTTTTTTTCG-3' as an anchored primer and 5'-TACAACGAGG-3' as a random arbitrary primer. The arrow indicates a reproducible PCR-amplified cDNA fragment that appears to be induced only in degenerating tissues (hippocampus and piriform cortex) at 6 and 12 h after kainic acid injection. In the hippocampus and piriform cortices, baseline levels of expression are seen in control animals and at the 3-h time point. By comparison, only baseline levels of expression are observed in the parietal cortex, a tissue in which seizure-induced neuronal degeneration is not observed.

```

CGCAGACTGGCAGCAGCGTCCGTCGGCGCGGCCACCTCCTCGCCCTTGCCAACCATG 60
GGGCCAACTCGCAACTCTTAAGGCTCAGCCTCGGGCCAAAGGAAATCAGAGAAGCTCGGA 120
GCAGAAGCCAAAGATGAGTTTCCGCAAGGAGGACGGGGTGAGCAGCCTGTGCCAGAAGGCG 180
      M S F R K E D G V S S L C Q K A 16
CTGCACATCATCACCAGCTGTGCTTCGCGGGCCAGGTGGAGTGGGACAAGTGTTCGGGC 240
L H I I T E L C F A G Q V E W D K C S G 36
ATCTTCCAGCCGATAGGAGCGGCCAGGGCGGAGGTGGCACAGACATTTCAGTCAGCCTG 300
I F P A D R S G Q G G G G T D I S V S L 56
TTAGCAGTTGTTGTAAGCTTCGTGGCTGGCCCTGCTGGTTGTCCTCCCTTTCGTCTTC 360
L A V V V S F C G L A L L V V S L F V F 76
TGAAGTTGTGCTGGCCCTGCTGGAAGAGCAAGCTCGTGGCCCAATGTCAAGTACCTT 420
W K L C W P C W K S K L V A P N V S T L 96
CCGCAGGCATCTCAAGTCTCAACTGAGGTTTTGAGACCCGAAGAGAAAAAAGAAGTC 480
P Q S I S S A P T E V F E T E E K K E V 116
GAAGAAAATGAAAAGCCAGCACCACAAAAGCTATTGAGCTGCAATAAAAAATCAGCCACACA 540
E E N E K P A P K A I E P A I K I S H T 136
TCCCGGACATCCAGCAGAAGTGCAAACTGCTTTAAAGGAGCATTTAATTAACATGCC 600
S P D I P A E V Q T A L K E H L I K H A 156
CGTGTGCAGAGGCAAAACGACCGATCCTACATCTTCATCCCGCCACAATTCTTCAGGAGG 660
R V Q R Q T T D P T S S S R H N S F R R 176
CACCTACCAAGGCAAAATGAACGTCTCCAGTGTGACTTTAGCATGGGCAGGCAACCTGTC 720
H L P R Q M N V S S V D F S M G T E P V 196
TTACAAGAGGAGAAAACAGAACCCAGCATCGGGAGGATAAAAACCGGAACCTATAAGCAG 780
L Q R G E T R T S I G R I K P E L Y K Q 216
AAATCAGTTGACTCCGAGGGCAACAGAAAAGACGACGTCAAACCTGTGGGAACTTAAC 840
K S V D S E G N R K D D V K T C G K L N 236
TTTGCCTCCAGTACGATTATGAAAATGAACTCCTAGTTGTTAAAATTAATCAAGCTCTA 900
F A L Q Y D Y E N E L L V V K I I K A L 256
GATCTCCAGCTAAAGATTCCACAGGAACCTCTGATCCTTATGTGAAGATCTATCTTCTT 960
D L P A K D S T G T S D P Y V K I Y L L 276
CCGGCAGGAAGAAGAAATTTCCAGACCCGTGTGCACCGGAAGACTTTAAACCTCTGTTC 1020
P D R K K K F Q T R V H R K T L N P L F 296
GATGAGCTATTTTCAGTTCGGTGGTTTACGATCAGCTAAGCAACCGCAAAATACACTTT 1080
D E L F Q F P V V Y D Q L S N R K L H F 316
AGTATATATGATTTTGACAGATTTTCCAGACACGACATGATGGGGAAGTATTCTTGTAT 1140
S I Y D F D R F S R H D M I G E V I L D 336
AATTTATTTGAAGTCTCTGATCTCCAGGGAAGCCACAGTATGGAAGATATCCACTGT 1200
N L F E V S D L S R E A T V W K D I H C 356
GCAACCACAGAAAGCATGGACCTGGGCGAAATCATGTTTTCCCTTTGCTATTTGCCAAT 1260
A T T E S M D L G E I M F S L C Y L P T 376
GCTGGTCGATGACCTTGAAGTGTGATCAAGTGCAGAAATCTGAAGGCAATGGACATTACC 1320
A G R M T L T V I K C R N L K A M D I T 396
GGATCATCAGATCCTTATGTCAAAGTGTCTCTGATGTGTGAGGGCCGAAGACTTAAAAA 1380
G S S D P Y V K V S L M C E G R R L K K 416
AGAAAAAACAACACAAAAGAAAATACTCTCAATCCCGTGTACAATGAAGCATTATTTTC 1440
R K T T T K K N T L N P V Y N E A I I F 436
GATATCCCTCCAGAAAATGTGGACAGGTGACGCTGTGCATTGCGGTATGGATTATGAC 1500
D I P P E N V D Q V S L C I A V M D Y D 456
AGGGTGGGACACAATGAGGTCATAGGTGTGTGCGAACTGGACTAGACGCTGAGGGTCTT 1560
R V G H N E V I G V C R T G L D A E G L 476
GGAAGAGACCAATTGGAATGAAATGCTGGCCTATCACCAGGCAATCACACACTGGGAC 1620
G R D H W N E M L A Y H R K P I T H W H 496
CCCTTG 1626
P L 498
    
```

FIG. 2. Nucleotide and predicted amino acid sequence of synaptotagmin X. Single letter amino acid codes are used, numbering from the first in-phase ATG codon. The putative transmembrane domain is boxed, and the two C2 domains are indicated by shading. Sequence information from a small portion of the C-terminal tail of *syt X* is incomplete.

Expression of *syt X* mRNA in Rat Brain Tissue. The expression of *syt X* mRNA was examined in the hippocampus, piriform cortex, and parietal cortex by Northern blot analysis (Fig. 4A).

Syt VI MSGVWAGGPRCQAALAVLASLRCRARPPPLGLDVEVCQSFELQPPEQSPSAADS 54
 Syt X MSFRKEDGVSSLCQKALHIITELCFAGQVEWDKCSGIFPADRSGGGGGT 50
 p65C MSGDGEDELCRNALALVNELCFSVRGNHNNEKCEFSYLLRRDRTRHIET 51

Syt VI GTSVSLQVIVVIVCGVALVAFVFLFKLCKMPVRRNREASS---PSSANDASEI 105
 Syt X DISVSLIANVVSFEGGLALLVVSLVFKLCKPCPKSKLVAP---NVSTLQPSIS 101
 p65C DISVSLLSVITTFEGIVLGVSLVSVKLCWIPWRDGLNPQRDRSQHHPQHLL 105

Syt VI LOSPSSRGNMADKLDKPS-----ALGFLAAVKTSHTSPTDPAEVQMSV 149
 Syt X SAPTEVFETEKKVEEENEKPE-----APKAIHPAIKTSHTSPTDPAEVQTL 148
 p65C HHHHSFTDLTVERVDCGPEMPERSYLDLESYPVSGIKLSQTSPTDIPVDTSSGS 159

Syt VI KEHIMRHTKLRDTTTEPASSTRHTSFKRLRDRMHVSSVDYGNELPPAA--AQ 201
 Syt X KEHLIKHARVDRDTTPTSSSRHNSFRRLRDRMNVSSVDFSMGTEPVLQRGET 202
 p65C KENNIPNAHSQQVSAAPPATRFNSLPRPIQQQLSSP---EFGTQADEKV---IQ 208

Syt VI PLSIGRTKPELYKQKSVQDGEAKSEAAKSCCKINFSLRVDESSTIIVRTLKAF 255
 Syt X RTSIGRTKPELYKQKSVQSEGNRDKDVKTCCKLNFALQVYENELIVKTIKAL 256
 p65C VTSIGRTKPELYKQKSIIT-EAKKHQVNCGRINFMRLRTITTEQVVKLTKAL 261

Syt VI DLPKDFGCSDDPYVKIYLLPDRKCKLQTRVHRKTLNPTFDENHFHPVYEEEA 309
 Syt X DLPKDFGCSDDPYVKIYLLPDRKCKLQTRVHRKTLNPTFDENHFHPVYDQLS 310
 p65C DLPKDFGCSDDPYVKIYLLPDRKCKLQTRVHRKTLNPTFDENHFHPVFNELQ 315

Syt VI DRKHLISVDFDRFRSHDMIGEVILDNLFASDLRSRETSIKKOTQYATSESVDL 363
 Syt X NRKLFHSYDFDRFRSHDMIGEVILDNLFVSDLSREATVKKDHCATITSMDL 364
 p65C NRKLFHSYDFDRFRSHDLIGQVLDNLLFSDLSREATVKKDHCATITSEKADL 369

Syt VI GEFMSFLCYLPTAGRLITLIVLCKRNLKAMDITGSDPYVKVSLVLDGRRLKRRK 417
 Syt X GEFMSFLCYLPTAGRLITLIVLCKRNLKAMDITGSDPYVKVSLVLDGRRLKRRK 418
 p65C GEFMSFLCYLPTAGRLITLIVLCKRNLKAMDITGSDPYVKVSLVLDGRRLKRRK 423

Syt VI ITTKKNTLNPVYNEALIFDIPENVDVSLGIAVMDDYDRVGHNEVIGVCRVGLS 471
 Syt X ITTKKNTLNPVYNEALIFDIPENVDVSLGIAVMDDYDRVGHNEVIGVCRVGLD 472
 p65C ITTKKNTLNPVYNEALVFDIPENMEHNVVITAVMDYDCTGHNEVIGVCRVNA 477

Syt VI AEGLRDHWNEMLAYRKPITAHNHCIAEVKKSFKEGTPRL----- 511
 Syt X AEGLRDHWNEMLAYRKPITAHNHPIIEEKMVSMTKSFAGTGATKPVITIV 498
 p65C TDGPGREHWNEMLANRKPITAEVHQLIEEKMVSMTKSFAGTGATKPVITIV 531

Syt VI -----
 Syt X -----
 p65C ESPHSV----- 537

FIG. 3. Alignment of rat and marine ray predicted synaptotagmin amino acid sequences. The amino acid sequences of *syt VI* and *syt X* from rat and p65C from marine ray are aligned. Identical amino acid residues for all three genes are highlighted in black. The predicted *syt X* protein is most similar to *syt VI* and p65C, with overall identities of 62% and 52%, respectively. These three synaptotagmin genes share an additional region of amino acid homology that is not found in other synaptotagmin family members. This region is located between the transmembrane domain and the two C2 domains.

This experiment revealed that the *syt X* gene was rapidly and transiently induced in specific brain regions in response to kainic acid-induced status epilepticus. A single 8.0-kb transcript was induced in the hippocampus and piriform cortex but not in the parietal cortex. In the hippocampus, the *syt X* message was elevated at 3 h, strongly induced at 6 h, and returned to basal levels by 12 h after kainic acid administration. In the piriform cortex, a smaller level of *syt X* message induction was observed at 3 and 6 h after kainic acid administration. The piriform cortex also appeared to have a higher level of constitutive *syt X* expression in comparison to the hippocampus and parietal cortex. *In situ* hybridization experiments were performed to verify the tissue-specific pattern of *syt X* gene expression. These experiments confirmed that the *syt X* gene was induced in specific brain regions in response to kainic acid-induced status epilepticus. The *syt X* gene showed tissue-specific expression in layer II of the piriform cortex and the dentate granule cells of the hippocampus (Fig. 4B). Most other brain regions showed very low basal level *syt X* gene expression.

The pattern of gene expression observed in both differential display and Northern blot analyses demonstrated an increase in *syt X* gene expression in response to seizure activity. However, the time course of *syt X* gene expression was not completely consistent between these experiments. The difference in these results may be explained by the variability in seizure activity between animals used in differential display and those used in Northern blot analyses (7). *In situ* hybrid-




FIG. 4. (A) Northern blot analysis of *syt X* expression. Poly(A)⁺ RNA from parietal cortex, hippocampus, and piriform cortex at 0, 3, 6, 12, and 24 h after kainic acid-induced seizures was probed with *syt X*. The probe identifies a single message that is 8.0 kb in length. The blot was also probed with a β -actin oligonucleotide for the purpose of quantitation. (B) *In situ* hybridization of rat brain sections using an oligonucleotide probe specific for the *syt X* gene. Coronal section control and 6-h kainic acid-treated rat brain. Examination of control and kainic acid-treated animals revealed that *syt X* is expressed in the dentate granule cells of the hippocampus and layer II of the piriform cortex.

ization results also showed some variability in the time course of *syt X* gene expression in response to seizure activity (data not shown). It also should be noted that differential display was primarily useful as a screening tool for the identification of differentially expressed genes and not as a quantitative measure of gene expression.

The Ca²⁺-dependent release of neurotransmitters and neuropeptides from presynaptic nerve terminals is the central event in synaptic neurotransmission (12). Recent genetic and electrophysiological evidence suggests that synaptotagmin I plays an integral role in synaptic vesicle fusion and neurotransmitter release (20–24). However, at least nine other members of the synaptotagmin gene family have been identified, and the role of these genes in synaptic vesicle function is not well understood. The *syt X* gene is unique in that it is structurally distinct from most other synaptotagmins and it demonstrates tissue-specific induction in response to seizure activity. It is particularly interesting that the *syt X* gene is induced in cells that project to neurons that undergo delayed cell death in response to excitotoxic injury (5, 7). The *syt X* gene is induced in the dentate granule cells, a region of the hippocampus that undergoes little or no seizure-induced cell death, so it is unlikely that this gene plays a direct role in the cell death process. However, *syt X* gene expression may play a role in modulating neurotransmitter release in response to excitotoxic neuronal activation. The expression of one other synaptotagmin gene, *syt IV*, has also been reported to be increased after kainic acid-induced seizures (25). It is possible that coordinate expression of specific synaptotagmin genes leads to changes in synaptic structure and function that underlie long term neuronal plasticity.

We thank K. Murphy and M. Peterson for their excellent technical assistance and E. M. Denovan-Wright for careful reading of the manuscript. This work was funded by grants from the Medical Research Council of Canada, Heart and Stroke Foundation of New Brunswick (R.W.C.), the Heart and Stroke Foundation of Nova Scotia (H.A.R.), and the Medical Research Council of Canada/SmithKline Beecham (R.W.C., H.A.R.).

- Liang, P. & Pardee, A. B. (1992) *Science* **275**, 967–971.
- Liang, P., Averboukh, L. & Pardee, A. B. (1993) *Nucleic Acids Res.* **21**, 3269–3275.

3. Olney, J. W., Rhee, V. & Ho, O. L. (1974) *Brain Res.* **77**, 507–512.
4. Nadler, J. V. (1981) *Life Sci.* **29**, 2031–2042.
5. Sperk, G. (1994) *Prog. Neurobiol.* **42**, 1–32.
6. Sheng, M. & Greenberg, M. E. (1990) *Neuron* **4**, 477–485.
7. Armstrong, J. N., Plumier, J.-C. L., Robertson, H. A. & Currie, R. W. (1996) *Neuroscience* **74**, 685–693.
8. Nedivi, E., Hevroni, D., Naot, D., Israeli, D. & Citri, Y. (1993) *Nature (London)* **363**, 718–721.
9. David, J.-D., Currie, R. W. & Robertson, H. A. (1994) *Neuroscience* **62**, 945–954.
10. Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. (1990) *J. Mol. Biol.* **215**, 403–410.
11. Li, C., Ullrich, B., Zhang, J. Z., Anderson, R. G. W., Brose, N. & Südhof, T. C. (1995) *Nature (London)* **375**, 594–595.
12. Südhof, T. C. (1995) *Nature (London)* **375**, 645–653.
13. Perin, M. S., Fried, V. A., Mignery, G. A., Jahn, R. & Südhof, T. C. (1990) *Nature (London)* **343**, 260–263.
14. Geppert, M., Archer, B. T. & Südhof, T. C. (1991) *J. Biol. Chem.* **266**, 13548–13552.
15. Mizuta, M., Inagaki, N., Nemoto, Y., Matsukura, S., Takahashi, M. & Seino, S. (1994) *J. Biol. Chem.* **269**, 11675–11678.
16. Hilbush, B. S. & Morgan, J. I. (1994) *Proc. Natl. Acad. Sci. USA* **91**, 8195–8199.
17. Hudson, A. W. & Birnbaum, M. J. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 5895–5899.
18. Craxton, M. & Goedert, M. (1995) *FEBS Lett.* **361**, 196–200.
19. Wendland, B., Miller, K. G., Schilling, J. & Scheller, R. H. (1991) *Neuron* **6**, 993–1007.
20. DiAntonio, A., Parfitt, D. & Schwarz, T. L. (1993) *Cell* **73**, 1281–1290.
21. Littleton, J. T., Stern, M., Schulze, K., Perin, M. & Bellen, H. J. (1993) *Cell* **74**, 1125–1134.
22. Nonet, M. L., Grundahl, K., Meyer, B. J. & Rand, J. B. (1993) *Cell* **73**, 1291–1305.
23. Geppert, M., Goda, Y., Hammer, R. E., Li, C., Rosahl, T. W., Stevens, C. F. & Südhof, T. C. (1994) *Cell* **79**, 717–727.
24. Martin, K. C., Hu, Y., Armitage, B. A., Siegelbaum, S. A., Kandel, E. R. & Kaang, B.-K. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 11307–11311.
25. Vician, L., Lim I. K., Ferguson, G., Tocco, G., Baudry, M. & Herschman, H. R. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 2164–2168.